Leading Biotech Company Announces FDA Agreement For Acne Treatment

Dermata Therapeutics Ushers in a New Era for Acne Treatment with DMT310 Phase 3 Clinical Program.

Disclaimer: This article includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

Dermata Therapeutics, a leading biotechnology company, has recently announced its plans to begin enrolling patients in the DMT310 Phase 3 Acne Clinical Program in December 2023. This initiative is based on …